These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36695597)

  • 21. Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines.
    Zhang GF; Meng W; Chen L; Ding L; Feng J; Perez J; Ali A; Sun S; Liu Z; Huang Y; Guo H; Gao SJ
    J Med Virol; 2022 Dec; 94(12):5678-5690. PubMed ID: 35902378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains.
    Ying B; Whitener B; VanBlargan LA; Hassan AO; Shrihari S; Liang CY; Karl CE; Mackin S; Chen RE; Kafai NM; Wilks SH; Smith DJ; Carreño JM; Singh G; Krammer F; Carfi A; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    Sci Transl Med; 2022 Feb; 14(630):eabm3302. PubMed ID: 34846168
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
    Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H
    Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection.
    Pérez P; Lázaro-Frías A; Zamora C; Sánchez-Cordón PJ; Astorgano D; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2021; 12():824728. PubMed ID: 35154086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
    de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern.
    Tostanoski LH; Yu J; Mercado NB; McMahan K; Jacob-Dolan C; Martinot AJ; Piedra-Mora C; Anioke T; Chang A; Giffin VM; Hope DL; Wan H; Bondzie EA; Mahrokhian SH; Wrijil LM; Bauer K; Pessaint L; Porto M; Piegols J; Faudree A; Spence B; Kar S; Amanat F; Krammer F; Andersen H; Lewis MG; Wegmann F; Zahn R; Schuitemaker H; Barouch DH
    Sci Transl Med; 2021 Nov; 13(618):eabj3789. PubMed ID: 34705477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Simplified SARS-CoV-2 Mouse Model Demonstrates Protection by an Oral Replicon-Based mRNA Vaccine.
    Jawalagatti V; Kirthika P; Hewawaduge C; Park JY; Yang MS; Oh B; So MY; Kim B; Lee JH
    Front Immunol; 2022; 13():811802. PubMed ID: 35250985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
    Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
    mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
    Martinez DR; Schäfer A; Leist SR; De la Cruz G; West A; Atochina-Vasserman EN; Lindesmith LC; Pardi N; Parks R; Barr M; Li D; Yount B; Saunders KO; Weissman D; Haynes BF; Montgomery SA; Baric RS
    Science; 2021 Aug; 373(6558):991-998. PubMed ID: 34214046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MVA-CoV2-S Vaccine Candidate Neutralizes Distinct Variants of Concern and Protects Against SARS-CoV-2 Infection in Hamsters.
    Boudewijns R; Pérez P; Lázaro-Frías A; Van Looveren D; Vercruysse T; Thibaut HJ; Weynand B; Coelmont L; Neyts J; Astorgano D; Montenegro D; Puentes E; Rodríguez E; Dallmeier K; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():845969. PubMed ID: 35371064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
    J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical immunogenicity and efficacy of a candidate COVID-19 vaccine based on a vesicular stomatitis virus-SARS-CoV-2 chimera.
    Espeseth AS; Yuan M; Citron M; Reiserova L; Morrow G; Wilson A; Horton M; Rukhman M; Kinek K; Hou F; Li SL; Li F; Choi Y; Heidecker G; Luo B; Wu G; Zhang L; Strable E; DeStefano J; Secore S; Mukhopadhyay TK; Richardson DD; Sayeed E; Welch LS; Bett AJ; Feinberg MB; Gupta SB; Cooper CL; Parks CL
    EBioMedicine; 2022 Aug; 82():104203. PubMed ID: 35915046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission.
    Ye C; Park JG; Chiem K; Dravid P; Allué-Guardia A; Garcia-Vilanova A; Pino Tamayo P; Shivanna V; Kapoor A; Walter MR; Kobie JJ; Plemper RK; Torrelles JB; Martinez-Sobrido L
    Microbiol Spectr; 2023 Jun; 11(3):e0065323. PubMed ID: 37191507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.